In this respect, vascular endothelial growth factor (VEGF) and mechanistic target of rapamycin (mTOR) pathways have been established as relevant targets in RCC, since most patients suffer from the aberrant activation of these pathways due to genetic and/or epigenetic alterations. This evidence concerns the gene VEGFA and renal cell carcinoma.